Stasinos Chr. Sikalias · The science of compounding

Menthol 1% and thymol 1% rubefacient in rosemary spirit

CGR-ES-079 · FN/2003/PO/026 SOLUCIÓN RUBEFACIENTE

For local reviewCGR-ES-079Spain · AEMPS

Documented bibliographic addition; requires local scientific approval before use as a master formulation record.

The master formula and patient leaflet differ in quantity/units. The explicit master formula is used; this interpretation requires approval before preparation. See Notes.

Dosage formSolution for external pharmaceutical use
Reference batch100 mL
Monograph version5.0
Source packagev5

Source formula

IngredientSource quantity
Racemic menthol1 g
Thymol1 g
Rosemary spirit PO035q.s. ad 100 mL

Quantities refer to the source batch. This website does not automatically scale formulas, assign doses or calculate BUD.

Description

Documented in source

Clear colourless liquid with a characteristic odour.

References: [1]

Use and action

Documented in source

AEMPS describes external rubbing for symptomatic relief of muscle/joint pain and mild itching.

References: [1]

Specifications

Partial evidence

Clear colourless liquid with a characteristic odour. Quantities/raw-material quality follow §3. No specific numerical finished-product assay limit is provided.

References: [1]

Light

Documented in source

The finished preparation is stored protected from light under the monograph.

References: [1]

Air

Partial evidence

Ethanol generates vapour; limit time in open vessels. Evaporation can change composition (editorial process assessment).

References: [6]

Water and solubility

Partial evidence

Ethanol is miscible with water. This does not establish that all dissolved actives remain soluble after dilution.
Racemic menthol is practically insoluble in water and very soluble in ethanol under PA021.

References: [4] · [6]

Humidity

Not established

No specific finished-product information is established in the reviewed sources. Additional evidence is required before defining a specification.

References: [1]

Temperature

Partial evidence

Finished-product storage: Below 25°C, tightly closed and protected from light. Processing follows the method-specific temperatures.

References: [1]

pH and related incompatibilities

Not established

No specific finished-product information is established in the reviewed sources. Additional evidence is required before defining a specification.

References: [1]

Other incompatibilities

Partial evidence

Menthol forms eutectic mixtures with camphor/thymol; incompatible with strong oxidants.
Thymol: incompatible with oxidants/alkalis; proteins reduce antiseptic action.
Ethanol is incompatible with strong oxidants.

References: [4] · [5] · [6]

Ingredient-specific information

Partial evidence

Exact identities: Ρακεμική μενθόλη / Racemic menthol; Θυμόλη / Thymol; Οινόπνευμα δενδρολίβανου PO035 / Rosemary spirit PO035. Use pharmacopoeial raw materials of the referenced edition, with CoA verification. Do not arbitrarily change salt, hydration state or strength. Record the actual q.s. amount in the batch.

References: [1]

Compounding conditions

Documented in source

Laboratory environment under the referenced AEMPS procedure: 25±5°C and relative humidity ≤60%, unless the specific formulation requires otherwise. Room temperature differs from processing temperature.

References: [2]

Personal protective equipment

Partial evidence

Clean protective clothing and head covering under AEMPS PN/L/PG/002/00. Use suitable gloves where contact is possible and respiratory/eye protection where powder handling requires it. Exact glove material, ventilation and respiratory protection must follow the SDS and local exposure assessment.
Menthol: eye protection and prevention of contact/dust inhalation.

References: [3] · [4]

Risks and precautions

Partial evidence

Possible irritant/allergic dermatitis and inhalation irritation. Ingestion can cause severe toxicity. The vehicle has a high alcohol content.
Ethanol: flammable vapour; control ignition sources and provide suitable ventilation. Final classification depends on concentration/mixture.

References: [1] · [6]

BUD rationale

Partial evidence

The specific monograph states 3 months under its specified conditions. This is a source period, not independently verified stability of the local batch. Match composition, preservative, container and storage, check applicable requirements and obtain responsible approval. The actual date remains blank.

References: [1]

Bases and dependencies

Documented in source

CGR-ES-076 — Αλκοολικό διάλυμα αιθέριου ελαίου δενδρολίβανου 5% / Rosemary essential oil alcoholic solution 5% v/v
Referenced bases are included in the package; also check their dependencies.

References: [1] · [7]

Equipment

Editorial checklist

Balance with suitable resolution, mortar/spatula, suitable mixing vessels and final container. Add volumetric equipment for mL, a controlled water bath where melting is specified and a suitable filter where required. Analytical equipment follows the QC methods.

References: [2]

Preparation procedure

Documented in source

1. Prepare and check rosemary spirit 5% PO035.
2. Dissolve menthol and thymol in part of the vehicle.
3. Filter and make up to 100 mL with the same vehicle under PN/L/FF/007/00.

References: [1] · [2]

Observations

Partial evidence

The master formula is 100 mL. The leaflet heading “100 g” conflicts with its own ad 100 mL and is not used to change the formula basis.

References: [1]

Packaging

Documented in source

Amber glass bottle.

References: [1]

Labelling

editorial_specimen

Menthol 1% and thymol 1% rubefacient in rosemary spirit
Quantity: _____ · Batch: _____ · Prepared: _____ · Use by: _____
External use only. Storage: Below 25°C, tightly closed and protected from light.
Patient/directions or laboratory use: _____ · Pharmacy/telephone: _____
Flammable. Keep away from flames. Do not swallow.
Specimen for pharmacist adaptation; not a final approved label.

References: [1] · [6]

Quality control

Partial evidence

Under AEMPS: organoleptic properties and final mass and/or volume. For batches: colour RFE 2.2.2, clarity/opalescence RFE 2.2.1, relative density RFE 2.2.5, pH under PN/L/CP/001/00 and microbiological testing under RFE 5.1.4. This formula provides no numerical pH/density limits or specific active assay.

References: [1] · [2]

Storage

Documented in source

Below 25°C, tightly closed and protected from light.

References: [1]

Dispensing and directions

Documented in source

DO NOT SWALLOW. EXTERNAL USE ONLY. The source gives 2–3 applications/day with gentle rubbing. Do not use under age 2, on open wounds or mucosa, or near the nose. Pregnancy/breastfeeding require medical assessment.

References: [1]

Sources and traceability

  1. FN/2003/PO/026 SOLUCIÓN RUBEFACIENTE

    FN/2003/PO/026 · Master formula §§3–4; packaging/storage §5; description §6; period §7; use/precautions §§8–12 and patient leaflet · A1 official formulary

    Review date reported in supplied metadata: 2026-09-10

  2. PN/L/FF/007/00 ELABORACIÓN DE SOLUCIONES

    PN/L/FF/007/00 · §4.3 environment; §4.4 method; §4.6 controls · A2 official technical guidance

    Review date reported in supplied metadata: 2026-09-10

  3. PN/L/PG/002/00 INDUMENTARIA

    PN/L/PG/002/00 · Clothing and protective equipment · A2 official technical guidance

    Review date reported in supplied metadata: 2026-09-10

  4. FN/2003/PA/021 MENTOL RACÉMICO

    FN/2003/PA/021 · Raw-material properties, handling and incompatibilities · A1 official formulary

    Review date reported in supplied metadata: 2026-09-10

  5. FN/2003/PA/037 TIMOL

    FN/2003/PA/037 · Raw-material properties, handling and incompatibilities · A1 official formulary

    Review date reported in supplied metadata: 2026-09-10

  6. niosh_ethanol

    Official agency page · Raw-material properties, handling and incompatibilities · A2 official technical guidance

    Review date reported in supplied metadata: 2026-09-10

  7. FN/2006/PO/035 ALCOHOL DE ROMERO AL 5%

    FN/2006/PO/035 · PDF pp. 1–3 · A1 official formulary

    Review date reported in supplied metadata: 2026-09-10

  8. AEMPS — Aviso legal

    Policy checked 2026-09-10 · Reuse conditions · Rights policy, not clinical evidence

    Review date reported in supplied metadata: 2026-09-10

  9. BOE — Real Decreto 1495/2011, artículos 7–10 y anexo

    Policy checked 2026-09-10 · Reuse conditions · Rights policy, not clinical evidence

    Review date reported in supplied metadata: 2026-09-10

Provenance and reuse

Source: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Formulario Nacional. Original Greek/English rendering and restructuring: Greek Formulary Sikalias, Stasinos Chr. Sikalias, compounding.gr. Reuse basis: AEMPS legal notice and RD 1495/2011, Articles 7–10/Annex. Composition and units retained; references, distinct editorial notes and blank batch fields added. AEMPS endorsement is not implied. Edition code appears in the reference; NIPO 134-20-002-3 / 090-22-245-5. The PDFs do not state an exact internal revision date. Access checked 10 September 2026. CDC/NIOSH sources are freely available from CDC; brief technical paraphrases imply no CDC endorsement.

SHA-256 of the supplied PDF: 534e59fe77d815f71c9126c137d436d298f86acb0707e5deb24bd981605639d6